{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:45:23Z","timestamp":1771512323420,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/j.ctarc.2019.100151","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T03:08:24Z","timestamp":1557803304000},"page":"100151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Lahiru","family":"Ranasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Cotogno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Ledet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Bordlee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Degeyter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allie","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Manogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2019.100151_bib0001","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2019.100151_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ctarc.2019.100151_bib0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncr.30336","article-title":"Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and\/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial","volume":"123","author":"Loriot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2019.100151_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2019.100151_bib0005","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1634\/theoncologist.2017-0564","article-title":"Laboratory based biomarkers and liver metastases in metastatic castration-resistant prostate cancer","volume":"23","author":"Cotogno","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2019.100151_bib0006","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1470-2045(16)30560-5","article-title":"Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data","volume":"18","author":"Guinney","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2019.100151_bib0007","first-page":"1","article-title":"Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer","volume":"485","author":"Hiew","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.ctarc.2019.100151_bib0008","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","article-title":"Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration","volume":"19","author":"Smaletz","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2019.100151_bib0009","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.eururo.2014.09.022","article-title":"Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model","volume":"68","author":"Gravis","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2019.100151_bib0010","first-page":"1","article-title":"Anemia in men with advanced prostate cancer: incidence, etiology, and treatment","volume":"6","author":"Nalesnik","year":"2004","journal-title":"Rev. Urol."},{"key":"10.1016\/j.ctarc.2019.100151_bib0011","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.ctarc.2019.100151_bib0012","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2017.35.6_suppl.149","article-title":"Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): association with outcomes and evolution with therapy","volume":"35","author":"Sonpavde","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294218301394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294218301394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:17:25Z","timestamp":1762841845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294218301394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":12,"alternative-id":["S2468294218301394"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2019.100151","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2019.100151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100151"}}